Palatin reports Q3 revenue $3.4M, consensus $2.73M

Reports Q3 total prescriptions dispensed increased 27% over the prior quarter and increased 147% over the comparable quarter in 2022. "Vyleesi’s continued quarter over quarter growth across multiple value metrics, most importantly net product revenue and prescriptions dispensed, is a direct result of our focused business strategy: a targeted digital marketing campaign to both consumers and healthcare professionals," stated Carl Spana, President and CEO of Palatin. "We are particularly pleased that quarterly net product revenue for Vyleesi continues to exceed Vyleesi quarterly operating expenses."